Author: Repair User
i.d.e.a. Fund Recipient
We’re pleased to be named as one of the TechAlliance-supported companies in Cohort 3 of i.d.e.a. Fund! This program is funded by the Government…
Re:Pair Genomics Team Competed in the Hult Prize semifinals in Monterrey, Mexico
In June 2024, we competed in the Hult Prize Semifinals in Mexico. After the preliminary round, Re:Pair Genomics was selected as one of the…
Re:Pair Genomics Showcases Technology at MaRS Impact Health 2024
On June 13, 2024, Re:Pair Genomics was invited to present and feature our venture in the Biotech Expo Stage, organized by MaRS Impact Health…
Re:Pair shines in 2nd place at BBTV pitch competition
Building a BioTech Venture, otherwise known as BBTV, is a program offered at the University of Toronto (UofT), by Medicine by Design. Medicine by…
Hult Prize Competition: A Day of Innovation and Achievement
On 21st February 2024, our team embarked on an extraordinary journey to participate in the prestigious Hult Prize competition, a global platform known for…
Re:Pair Genomics Presents Poster at the UofT AI Conference
Our team had an incredible day at ConferenceX, held in the MaRS Discovery District! 🚀 The event was truly inspiring, filled with stories from…
Re:Pair Genomics Presents Poster at the Cell & Gene Therapy West Coast Symposium
On September 7, California Life Sciences and Johnson & Johnson Innovation co-hosted a West Coast Symposium focusing on Cell and Gene Therapy – Advancing…
In silico prediction and in vivo testing of promoters targeting GABAergic inhibitory neurons
Impairment of GABAergic inhibitory neuronal function is linked to epilepsy and other neurological and psychiatric disorders. Recombinant adeno-associated virus (rAAV)-based gene therapy targeting GABAergic…
Pitch Perfect 2022 Recap & Winners Announcement
On Wednesday November 9th, 2022, H2i welcomed founders, students, faculty, mentors and more to Pitch Perfect 2022! Marking H2i’s first in-person event since early…
Hatchery NEST 2022 Demo Day
Over 90% of gene therapy clinical trials fail at the moment. The reasons for failure include adverse effects and low efficacy of the treatment.…